Article
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.
PLoS medicine - 1 Sept 2011
Suppiah Vijayaprakash, Gaudieri Silvana, Armstrong Nicola J, O'Connor Kate S, Berg Thomas, Weltman Martin, Abate Maria Lorena, Spengler Ulrich, Bassendine Margaret, Dore Gregory J, Irving William L, Powell Elizabeth, Hellard Margaret, Riordan Stephen, Matthews Gail, Sheridan David, Nattermann Jacob, Smedile Antonina, Müller Tobias, Hammond Emma, Dunn David, Negro Francesco, Bochud Pierre-Yves, Mallal Simon, Ahlenstiel Golo, Stewart Graeme J, George Jacob, Booth David R
Abstract excerpt
BACKGROUND: To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIFN/R). Viral clearance is achieved in 40%-50% of patients. Interleukin 28B (IL28B) genotype predicts treatment-induced and spontaneous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
